The global AI in pharmaceutical market is on a trajectory of substantial growth, with a projected valuation of US$4,451.6 Mn by the end of 2030, up from approximately US$807.2 Mn in 2018. This impressive growth is underpinned by the widespread adoption of Artificial Intelligence (AI) technologies across the pharmaceutical industry, from drug discovery to development and personalized treatment.

Read More: https://www.fairfieldmarketresearch.com/report/ai-in-pharmaceutical-market

Between 2023 and 2030, the market is set to achieve a robust Compound Annual Growth Rate (CAGR) of 19.1%, highlighting the transformative potential of AI in shaping the pharmaceutical landscape.

A Paradigm Shift in Pharmaceutical Industry

AI in the pharmaceutical sector represents a pivotal transformation, where AI technologies empower researchers and healthcare professionals to make data-driven decisions, reduce costs, and enhance patient outcomes. This paradigm shift is poised to revolutionize drug discovery and development, making it more efficient and cost-effective.

Key Market Insights

1. Transforming Drug Discovery and Development

AI is emerging as a game-changer in drug discovery and development, harnessing the power of data analytics, machine learning, and natural language processing. By expediting research, AI lowers costs and improves the chances of developing effective medications. As AI technology evolves, its role in reshaping the pharmaceutical sector becomes increasingly significant.

2. Vital Report Findings

The global AI in pharmaceutical market is expected to reach US$4,451.6 Mn by 2030, surging from US$807.2 Mn in 2018.
The burgeoning use of AI in drug discovery and development, predictive forecasting, pharmaceutical marketing, and personalized treatment will be key growth drivers.
Asia Pacific is poised to be the fastest-growing market, while North America continues to lead the way.
3. Driving Factors

Increasing Adoption Potential in New Drug Discovery AI has become indispensable in the pharmaceutical sector, especially in the wake of the COVID-19 pandemic. It aids in identifying disease patterns accurately, leading to the discovery of optimal drug compositions. Embracing AI reduces research and development costs, minimizes errors, and accelerates drug development, contributing to the creation of affordable and effective medicines.

Rapidly Rising Adoption of AI in Drug Discovery and Development AI is becoming increasingly integral to drug discovery and development. It analyzes vast datasets to identify potential drug targets, optimize drug molecules, and predict efficacy and safety. AI's role in identifying biomarkers for personalized treatment and expediting drug development cannot be overstated.

Booming Advanced Technology-enabled Personalized Treatment AI empowers healthcare professionals to provide personalized treatment by analyzing real-time patient data. Machine learning and AI-driven data analysis offer early insights into patient conditions, improving diagnostic capabilities. Predictive forecasting, clinical trial optimization, and pharmaceutical marketing also benefit from AI, driving market growth.

4. Key Segments

Drug Discovery: A Pioneering Application Area The drug discovery segment is a major contributor to the AI in pharmaceutical market, valued at US$291.7 Mn in 2022 and projected to reach around US$1,225.9 Mn by 2030. AI's influence in drug discovery spans target identification, clinical trials, and molecular pathway analysis, significantly improving efficiency and success rates.

Natural Language Processing: Dominating Technology Segment Natural language processing (NLP) is a pivotal technology in the pharmaceutical industry, enabling the extraction, organization, and analysis of unstructured text data. NLP accelerates the identification of drug candidates, targets, and biological pathways, expediting drug discovery.

5. Regional Growth Opportunities

North America's Dominant Position North America, a global technology hub, is expected to hold a substantial share in the AI in pharmaceutical market. AI applications in clinical trials, drug discovery, and drug development, coupled with the rising burden of chronic diseases, are driving market growth. Industry leaders and cross-industry collaborations further bolster the region's position.

The United States Leads Investment Global investment in AI in the pharmaceutical industry is soaring, with the United States taking the lead. Investment is projected to reach US$6.3 Bn by 2025, with nearly half of the total coming from the US. China, the UK, Germany, France, and Japan are also actively investing in AI to enhance drug discovery and development capabilities.

Asia Pacific: The Fastest Growing Regional Pocket The Asia Pacific region is experiencing rapid growth, with a CAGR of 20.8%. AI adoption in the pharmaceutical industry is gaining momentum, particularly in countries like China, Japan, India, and South Korea. AI is accelerating drug discovery, optimizing drug designs, and tailoring treatment plans to individual patients' characteristics. The region's focus on precision medicine and AI-driven drug repurposing further fuels growth.

6. Competition Landscape

The AI in pharmaceutical market is marked by intense competition, with companies and research institutions harnessing AI to advance drug discovery, development, and patient care. Key players include GNS Healthcare, Benevolent AI, Berg Health, Novo Nordisk, IBM Corporation, Alphabet Inc (DeepMind), General Electric Company, Pfizer Inc., Johnson & Johnson, and Novartis AG.

Our Trending Blogs:

https://medium.com/@swati_85544/global-ai-in-pharmaceutical-market-projected-to-reach-us-4-451-6-ddca7d8ebe37

Fairfield Market Research

London, UK

UK [phone]

USA (Toll-free) [phone]